Payment overview · 2025
General Payments
$194.75
10 reported records · 8 companies
Healthcare provider profile · identity verified
William L Short, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ABILENE, KS · NPI 1841300340
Verified facts
What the public records show
CMS Open Payments records show William L Short, MD received $194.75 in general payments during 2025 across 10 reported records.
Lilly USA, LLC accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.76 | 23.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.22 | 21.2% | 2 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $26.43 | 13.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.58 | 9.5% | 1 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $17.36 | 8.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.04 | 8.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.61 | 7.5% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $13.75 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $194.75 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.76 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $45.76 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $41.22 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $41.22 | 2 | 2025 |
Source payment records
|
|||||
| AQUACEL AG+ Normalized: aquacel ag |
Device | ConvaTec Inc. | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| AQUACEL FOAM Normalized: aquacel foam |
Device | ConvaTec Inc. | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
117 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 394 | 85 |
| Lisinopril | Lisinopril | 351 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 271 | 57 |
| Furosemide | Furosemide | 269 | 47 |
| Simvastatin | Simvastatin | 194 | 40 |
| Omeprazole | Omeprazole | 192 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 28 |
| Gabapentin | Gabapentin | 176 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 175 | 36 |
| Potassium Chloride | Potassium Chloride | 155 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 137 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 125 | 30 |
| Losartan Potassium | Losartan Potassium | 119 | 30 |
| Eliquis | Apixaban | 117 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 20 |
| Trazodone Hcl | Trazodone Hcl | 89 | 16 |
| Famotidine | Famotidine | 88 | 14 |
| Metformin Hcl | Metformin Hcl | 80 | 19 |
| Sertraline Hcl | Sertraline Hcl | 73 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | suppressed |
| Xarelto | Rivaroxaban | 69 | 15 |
| Meloxicam | Meloxicam | 68 | 12 |
| Tramadol Hcl | Tramadol Hcl | 67 | 18 |
| Warfarin Sodium | Warfarin Sodium | 62 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | suppressed |
| Ozempic | Semaglutide | 58 | suppressed |
| Memantine Hcl | Memantine Hcl | 57 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 11 |
| Lorazepam | Lorazepam | 50 | 16 |
| Pregabalin | Pregabalin | 47 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 11 |
| Atenolol | Atenolol | 41 | 14 |
| Spironolactone | Spironolactone | 41 | suppressed |
| Carvedilol | Carvedilol | 40 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | 11 |
| Alprazolam | Alprazolam | 38 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 17 |
| Digoxin | Digoxin | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 21 |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Clonazepam | Clonazepam | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $194.75 · 10 records | Lilly USA, LLC | ABRYSVO, AQUACEL AG+, AQUACEL FOAM, BEXSERO, Korlym, MOUNJARO, Miro3D, PEDIARIX, PENMENVY, PREVNAR 20, REXULTI, ZEPBOUND | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error